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| INTRODUC TI ON
Neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF), and its receptor, rearranged during transfection (RET), are essential for enteric nervous system (ENS) development and may also dynamically maintain the adult ENS by contributing to synapse formation, signal transmission, and neuronal plasticity.
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The critical role of RET in the development of the ENS has been well established with the identification of genetic loss-of-function mutations in Hirschsprung patients who suffer from colonic intestinal pseudo-obstruction due to variable lengths of bowel aganglionosis, often in association with loss-of-function mutations in RET. 5 This data combined with knockout mouse models that recapitulate human Hirschsprung's disease has provided insight into the role of RET in the development of the ENS. [5] [6] [7] [8] [9] Although the role of RET during the development of the ENS has been well established, the role of RET in the survival and plasticity of neurons in the adult ENS is not as well defined even though RET continues to be expressed throughout adulthood. 10 Recent data implicate RET in the maintenance and plasticity of the adult ENS.
Indeed, neurons within the submucosal and myenteric plexus of the adult human colon express RET and the co-receptors GFRα1
and GFRα2 while GDNF is expressed in the muscularis mucosa, circular and longitudinal muscle tissue. 10 Mechanistically, RET signaling is associated with the maturation of presynaptic axon terminals through regulating the expression of presynaptic proteins. [1] [2] [3] Systemic administration of GDNF in adult rodents significantly increases submucosal neuron density in both the small intestine and the colon.
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In the current study, we aimed to understand how neurotrophic factors affect ENS neuronal plasticity and function. Our data revealed that RET transcripts were co-expressed with ChAT in enteric ganglia. To understand the function of enteric RET, a potent, selective, and GI-restricted small molecule inhibitor of RET, GSK3179106, was employed. 12 We demonstrate that RET inhibition had profound effects on intestinal epithelial permeability, carbachol-induced secretion, and neostigmine-induced motility. Our data suggest that RET kinase activity in the adult gut functions as part of intrinsic neural pathways regulating gut mucosal and smooth muscle function.
| MATERIAL S AND ME THODS

| Reagent
yl)acetamide and is provided by GlaxoSmithKline.
| Animals
Male Sprague-Dawley rats (225-250 g, ~7-8 weeks old) were purchased from Charles River Laboratories (Wilmington, MA). Upon receipt, animals were housed 2 per cage in standard shoebox cages on Sanichip bedding, with standard rat chow and water available, ab libitum. Rats were housed on a 12:12 light:dark cycle (lights on at 6:00 AM) under controlled temperature (23 ± 2°C) and humidity (50% ± 20%).
All animal studies were conducted in accordance with the GSK Policy on the Care, Welfare and Treatment of Laboratory Animals, and use was approved by the University of Oklahoma Health Sciences Center
Institutional Animal Care and Use Committee (Approval #15-071). In the current study, female rats were excluded due to estrus cycle effects on GI function that remain incompletely understood.
| Detection of RET-expressing submucosal and myenteric neurons
RET in situ hybridization by RNAscope followed by sequential immunostaining against synaptophysin was achieved on an autostainer 
Key Points
• We hypothesized that a RET-mediated mechanism may regulate colonic ion transport and motility through modulation of cholinergic nerves.
• We found that a GI-restricted RET inhibitor attenuated carbachol but not bethanechol-induced secretion and reduced the prokinetic effect of neostigmine.
• Results provide evidence that RET-mediated mecha- added to the luminal side of the chambers and a second series of EFS was performed as described above. Tissues that received control prior to the 1st EFS series received compound prior to the 2nd EFS series and vice versa. Active ion transport was expressed as ΔI SC (μA/cm 2 ). For ligand-stimulated preparations, an EC 50 of carbachol
or serotonin (3.2 μmol/L) ligand was used.
| Ex vivo smooth muscle contractility
Following animal euthanasia, the colon was rapidly isolated, removed, and placed into ice-cold oxygenated Krebs buffer. Krebs buffer prepared as a solution as follows: 120 mmol/L NaCl, 
| Neostigmine-induced lower gastrointestinal transit
Rats were treated orally BID for 3. 
| Materials and reagents
| Data analysis
Data for ex vivo assays are analyzed using GraphPad Prism software 
| RE SULTS
| RET is expressed in adult submucosal and myenteric neurons of the ENS
RET expression in the adult peripheral nervous system has been described in the ENS within myenteric and submucosal ganglia. 
| RET inhibition affects cholinergic signaling in colonic mucosa
The ENS regulates multiple functions of the GI tract including peristalsis and secretion. 15, 16 To determine the effect of RET inhibition on GI mucosal secretion, colonic mucosal preparations were examined in an ex vivo organ bath Ussing chamber system for an effect on active ion transport assessed via electrophysiological F(1,9) = 27.01, P = 0.0001; two-way ANOVA) ( Figure 3A-C) . To understand the type of neurons that were specifically being stimulated by EFS, the non-selective acetylcholine receptor agonist, carbachol, was used to stimulate cholinergic signaling. Similar to the findings with EFS-induced response, GSK3179106 was able to decrease (4%-37% inhibition; F(3,28) = 16.00, P < 0.0001, oneway ANOVA) carbachol-induced active ion transport ( Figure 3D ).
In contrast, RET inhibition had no effect when bethanechol, a muscarinic receptor-selective acetylcholine receptor agonist, was used to stimulate active ion transport (F(3,28) = 0.982, P = 0.415, oneway ANOVA) ( Figure 4A ). RET inhibition, moreover, had no effect 
| RET inhibition attenuates colonic smooth muscle contraction and neostigmine-induced accelerated colonic transit
To understand the effect of RET inhibition on colonic smooth muscle function, contractility of the colon was examined in an ex vivo organ bath. While treatment of colonic muscle preparations with EFS-induced frequency-dependent colonic muscle contractions, there were no significant effects of the drug treatment at any frequency F I G U R E 3 RET inhibition decreases the response of colonic mucosa to electrical field stimulated or carbachol-induced active ion transport. GSK3179106 at (A) 10 (n = 10), (B) 100 (n = 10), or (C) 1000 nmol/L (n = 10) significantly decreased the change in I sc when stimulated with EFS from 2-64 Hz. *P < 0.05, **P < 0.01, ****P < 0.0001 Control compared to GSK3179106, repeated-measure two-way ANOVA, Bonferroni post-test. (D) GSK3179106 at both 100 and 1000 nmol/L inhibits carbachol-induced change in I sc (n = 8, all groups). (E) Representative trace of the inhibitory effect of GSK3179106 on the carbachol-induced increased in Isc. ***P = 0.0005, ****P < 0.0001 compared to vehicle, one-way ANOVA followed by a Bonferroni post-test GI prokinetic effects in both experimental models and human patients. [17] [18] [19] The acetylcholinesterase inhibitor, neostigmine, increases local concentrations of acetylcholine at the neuronal synapse by inhibiting the catabolism of acetylcholine, resulting in the potentiation of cholinergic signaling and increased GI motility. In a preclinical rat model, the administration of neostigmine induces an increase in lower GI motility as measured by an increase in fecal pellet excretion. 18 This model was utilized to determine the effect of RET inhibition on neostigmine-induced colonic motility. A single intraperitoneal injection of neostigmine alone significantly increased the excretion of fecal pellets, whereas GSK3179106 alone had no effect on normal lower GI motility ( Figure 6 ). However, oral administration of the RET inhibitor, GSK3179106, attenuated (44% inhibition; F(3,26) = 19.45, P < 0.0001, one-way ANOVA) neostigmine-induced lower GI motility in comparison with rats dosed with neostigmine alone suggesting a functional role for RET in cholinergic control of colonic motility.
| D ISCUSS I ON
In the current study, we sought to explore a role for RET in adult ENS.
We demonstrated that RET transcripts are expressed in mature ENS F I G U R E 4 RET inhibition effect on active ion transport induced by bethanechol, lubiprostone, linaclotide, vasoactive intestinal peptide, and serotonin. GSK3179106 at 10, 100, and 1000 nmol/L had no effect on active ion transport in colonic mucosa preparations when stimulated with (A) bethanechol
Representative traces of the effect of vehicle and 100 nmol/L GSK3179106 on the increase in Isc in response to each of the secretagogues are adjacent to the graphed data submucosal and myenteric ganglia, and using a selective RET inhibitor, we found that RET is functionally involved in the transmission of cholinergic secretomotor activity and lower GI motility. These findings provide a link to the identity and function of RET-expressing neurons in the adult ENS and how RET inhibition may be of therapeutic value for the treatment of intestinal disorders associated with increased secretion and accelerated GI transit such as IBS-D.
Recent work has identified the location of RET, GFRα1, and GFRα2 expression in neurons of both the submucosal plexus and the myenteric plexus of adult human colon. 10 This study confirms and extends these findings by identifying RET-expressing neurons within the submucosal and myenteric ganglia with the use of a specific antisense RNA probe for human or rat RET transcripts. A subset of submucosal and myenteric ganglia exhibit high levels of RET expression as evidenced by the RET antisense probe labeling of these cells. Moreover, in a subset of neurons the co-expression of ChAT identified these RET-expressing neurons as cholinergic.
To understand the functional implications of RET inhibition within the bowel, we used GSK3179106, a potent, selective, reversible, and GI-restricted RET inhibitor that is equally potent against the human and rat RET enzymes. 12 It is active in multiple cell-based assays of functional RET activity and is highly selective for RET as demonstrated by in vitro kinase assays and proteomic profiling in colon lysates. However, while we are confident that RET is the likely target for the observed findings utilizing GSK3179106 based on our findings and published literature, we cannot rule out the potential effects GSK3179106 may have on DDR1 and DDR2 as well as other kinases at high concentrations. Moreover, GSK3179106
is minimally absorbed through the GI tract when dosed orally resulting in low systemic bioavailability and negligible brain penetration. 12 These characteristics make GSK3179106 a useful tool for studying the effects of RET inhibition within the ENS without affecting systemic or central targets. Furthermore, GI restriction potentially provides for a higher therapeutic index and a better safety profile for a drug to treat intestinal disorders by eliminating side effects known to occur with systemically available kinase inhibitors.
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In the current study, ex vivo studies of the secretomotor reflex suggesting that bethanechol directly stimulates enterocytes. 27 Similarly, RET inhibition had no effect on secretagogue-induced ion transport using serotonin, VIP, lubiprostone, and linaclotide, which may indicate that secretagogue-responsive cells do not express RET. In fact, enterocytes did not express RET transcripts (data not shown); however, intestinal enterocytes have been shown to express receptors for the secretagogues assayed, likely indicating a direct stimulatory effect of the secretagogues on enterocytes. [27] [28] [29] [30] [31] Taken together, these findings suggest RET inhibition may affect the function of neurons expressing presynaptic F I G U R E 5 RET inhibition has a minor effect on electric fieldstimulated smooth muscle contractility at high concentration. The number of muscle preparations for each group was as follows: Vehicle (n = 25); 10 nmol/L GSK3179106 (n = 14); 100 nmol/L GSK3179106 (n = 10); 1000 nmol/L GSK3179106 (n = 10). *P < 0.05 vehicle compared to GSK3179106 treatment, one-way ANOVA, Dunnett post-test F I G U R E 6 RET inhibition attenuates lower gastrointestinal motility induced by neostigmine. Rats were dosed orally with either vehicle or 10 mg/kg GSK3179106 for 3.5 days BID prior to a single intraperitoneal injection of vehicle or 0.1 mg/kg neostigmine and the cumulative number of fecal pellets counted at 30, 60, 90, 120, and 150 minutes (n = 7-8/group). † † P < 0.01, † † † † P < 0.0001 vehicle compared to neostigmine treatment, one-way ANOVA, Bonferroni post-test; *P < 0.05, **P < 0.01 neostigmine alone compared to neostigmine and GSK3179106 treatment, one-way ANOVA, Bonferroni post-test nicotinic receptors. 32 Thus, the demonstration of RET inhibition on cholinergic neuron function may indicate the potential to affect other cholinergic GI functions such as the peristaltic reflex.
15
The ENS coordinates muscle contraction and relaxation to enable GI peristalsis. Cholinergic stimulation of enteric smooth muscle drives proximal contractions that result in a GI prokinetic effect. [17] [18] [19] To understand the effect of RET inhibition on colonic smooth muscle function, colonic smooth muscle contractility was examined in an ex vivo organ bath. Although ENS control of muscle contractility has been well established, RET inhibition had a modest inhibitory effect on smooth muscle contractility and only at high concentrations of RET inhibitor tested (1 μmol/L) suggesting a rather minor role for RET inhibition in the attenuation of EFS-induced muscle contraction and likely may represent an off-target effect given the high concentration of inhibitor at which the effect was observed. In contrast, in an in vivo model of neostigminestimulated lower GI transit, RET inhibition attenuated the induced prokinetic effect demonstrating that RET inhibition can functionally attenuate increased neural motor activity controlling proximal smooth muscle contractions.
| CON CLUS ION
In summary, the identification and characterization of a po- 
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